Primmune Therapeutics: Funding, Investors & Team (Sep 2026)
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Primmune Therapeutics has raised $17.0M across 2 funding rounds on record, the most recent a Series B of $8.6M announced in Jan 2026.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Primmune Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Primmune Therapeutics Funding Rounds
Primmune Therapeutics raised $8.4M in a Series A announced in Nov 2021.
4.2 years later, a Series B of $8.6M was announced in Jan 2026.
Primmune Therapeutics Founders and Leadership Team
Contact details for the Primmune Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Primmune Therapeutics Funding Compared to Other Biotechnology Startups
Primmune Therapeutics' latest round of $8.6M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Primmune Therapeutics in Biotechnology and San Diego
Companies Similar to Primmune Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Primmune Therapeutics Funding FAQs
What does Primmune Therapeutics do?
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
How much funding has Primmune Therapeutics raised?
Primmune Therapeutics has raised $17.0M across 2 rounds on record. The most recent is a Series B of $8.6M announced in Jan 2026.
When did Primmune Therapeutics last raise funding?
Primmune Therapeutics' most recent funding round on record is a Series B of $8.6M, announced in Jan 2026.
Who founded Primmune Therapeutics?
FundedIQ lists Paulo Rangel (Founder) at Primmune Therapeutics.
Who is the CEO of Primmune Therapeutics?
Charlie McDermott is listed as CEO at Primmune Therapeutics.
Where is Primmune Therapeutics headquartered?
Primmune Therapeutics is based in San Diego, California, United States.
How many employees does Primmune Therapeutics have?
Primmune Therapeutics is in the 1-10 employee band.
How does Primmune Therapeutics' funding compare to other Biotechnology startups?
Primmune Therapeutics' latest round of $8.6M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Primmune Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Primmune Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.